Based on the results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial showing an association between high-dose infliximab and worsened heart failure, TNFi is contraindicated in New York Heart Association class III and IV heart failure (16). The gene discussed is TNF; the disease is congestive heart failure.